Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 12/20 | 0.45 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26429785 | 0.89 | HCRTR1 (0.38) | CHRM4HCRTR1HCRTR2 | |
| SCHEMBL23744619 | 0.88 | CHRM4 (0.53) | CHRM4CHRM2CHRM1CHRM3 | |
| SCHEMBL23744565 | 0.86 | CCR3 (0.49) | CHRM4CCR3SIGMAR1 | |
| SCHEMBL23744451 | 0.85 | HCAR2 (0.44) | CHRM4CCR3CHRM2CHRM1 | |
| SCHEMBL23744177 | 0.85 | CHRM4 (0.53) | CHRM4CCR3HCRTR1HCRTR2CHRM2 | |
| SCHEMBL23744225 | 0.82 | CHRM2 (0.56) | CHRM4CHRM2CHRM1CHRM3 | |
| SCHEMBL23744226 | 0.82 | CHRM2 (0.56) | CHRM4CHRM2CHRM1CHRM3 | |
| SCHEMBL23744314 | 0.82 | NAAA (0.48) | CHRM4CCR3 | |
| SCHEMBL23744631 | 0.82 | NAAA (0.46) | CHRM4CCR3CHRM2CHRM1 | |
| SCHEMBL23744592 | 0.81 | CHRM4 (0.45) | CHRM4CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHRM4 1/4885CCR3 650/4885HCRTR1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.